| Inhibitor |
Pharmacological effect(s) |
Reference |
| FK866/K22.175, inhibitor of nicotinamide phosphoribosyltransferase (NamPRT) |
Potent antiangiogenic effects in murine renal cell carcinoma |
38
|
| APO866, inhibitor of NamPRT |
Potent inhibition of most cancer cells (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], mantle cell lymphoma [MCL], chronic lymphocytic leukemia [CLL], and T-cell lymphoma) |
39
|
| GMX1778, inhibitor of NamPRT |
Neuroblastoma regression and vessel maturation without inducing drug resistance in engrafted mice |
40
|
| Beta-lapachone, an orthonaphthoquinone |
Induction of cell death by activation of a futile cycling of the drug by the cytoplasmic two-electron reductaseNAD(P) H: quinone oxidoreductase (NQO1), DT-diaphorase and Xip3. Production of reactive oxygen species (ROS) at higher drug concentrations |
41
|
| Retinoic acid |
Induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in MCF7 cancer cells through transient increase in NADH level and mitochondrial oxidative turnover and a slow decline in reduced thiol level and mitochondrial membrane potential |
42
|
| Mycophenolic acid, a inhibitor of inosine 5'-monophosphate dehydrogenase (IMPDH) |
Enhanced cytotoxicity in tumor cell lines by binding to IMPDH at the nicotinamide sub-site of the NAD cofactor binding domain |
43
|
| Dicumarol, a NQO1 inhibitor |
Inhibition of NADPH: quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism |
44
|
| Sirtinol, a SIRT1 inhibitor |
Induction of senescence-like growth arrest, increased expression of plasminogen activator inhibitor, and impaired activation of mitogen-activated protein kinase (MAPK) pathways in human breast cancer MCF-7 cells and lung cancer H1299 cells. |
45
|
| Sulindac |
Induction of carcinogen metabolizing enzymes in human colon cancer cells |
46
|
| Salermide, a Sirtuin inhibitor |
Induction of cancer-specific proapoptotic effect in cancer cell s and mice by inhibiting SIRT1 and SIRT2 |
47
|
